Skip to main content
Journal cover image

Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.

Publication ,  Journal Article
Ahmed, AT; MahmoudianDehkordi, S; Bhattacharyya, S; Arnold, M; Liu, D; Neavin, D; Moseley, MA; Thompson, JW; Williams, LSJ; Louie, G; Skime, MK ...
Published in: J Affect Disord
March 1, 2020

BACKGROUND: Acylcarnitines have important functions in mitochondrial energetics and β-oxidation, and have been implicated to play a significant role in metabolic functions of the brain. This retrospective study examined whether plasma acylcarnitine profiles can help biochemically distinguish the three phenotypic subtypes of major depressive disorder (MDD): core depression (CD+), anxious depression (ANX+), and neurovegetative symptoms of melancholia (NVSM+). METHODS: Depressed outpatients (n = 240) from the Mayo Clinic Pharmacogenomics Research Network were treated with citalopram or escitalopram for eight weeks. Plasma samples collected at baseline and after eight weeks of treatment with citalopram or escitalopram were profiled for short-, medium- and long-chain acylcarnitine levels using AbsoluteIDQ®p180-Kit and LC-MS. Linear mixed effects models were used to examine whether acylcarnitine levels discriminated the clinical phenotypes at baseline or eight weeks post-treatment, and whether temporal changes in acylcarnitine profiles differed between groups. RESULTS: Compared to ANX+, CD+ and NVSM+ had significantly lower concentrations of short- and long-chain acylcarnitines at both baseline and week 8. In NVSM+, the medium- and long-chain acylcarnitines were also significantly lower in NVSM+ compared to ANX+. Short-chain acylcarnitine levels increased significantly from baseline to week 8 in CD+ and ANX+, whereas medium- and long-chain acylcarnitines significantly decreased in CD+ and NVSM+. CONCLUSIONS: In depressed patients treated with SSRIs, β-oxidation and mitochondrial energetics as evaluated by levels and changes in acylcarnitines may provide the biochemical basis of the clinical heterogeneity of MDD, especially when combined with clinical characteristics.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Affect Disord

DOI

EISSN

1573-2517

Publication Date

March 1, 2020

Volume

264

Start / End Page

90 / 97

Location

Netherlands

Related Subject Headings

  • Retrospective Studies
  • Psychiatry
  • Phenotype
  • Humans
  • Depressive Disorder, Major
  • Carnitine
  • 52 Psychology
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 17 Psychology and Cognitive Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ahmed, A. T., MahmoudianDehkordi, S., Bhattacharyya, S., Arnold, M., Liu, D., Neavin, D., … Mood Disorders Precision Medicine Consortium (MDPMC), . (2020). Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. J Affect Disord, 264, 90–97. https://doi.org/10.1016/j.jad.2019.11.122
Ahmed, Ahmed T., Siamak MahmoudianDehkordi, Sudeepa Bhattacharyya, Matthias Arnold, Duan Liu, Drew Neavin, M Arthur Moseley, et al. “Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.J Affect Disord 264 (March 1, 2020): 90–97. https://doi.org/10.1016/j.jad.2019.11.122.
Ahmed AT, MahmoudianDehkordi S, Bhattacharyya S, Arnold M, Liu D, Neavin D, et al. Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. J Affect Disord. 2020 Mar 1;264:90–7.
Ahmed, Ahmed T., et al. “Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.J Affect Disord, vol. 264, Mar. 2020, pp. 90–97. Pubmed, doi:10.1016/j.jad.2019.11.122.
Ahmed AT, MahmoudianDehkordi S, Bhattacharyya S, Arnold M, Liu D, Neavin D, Moseley MA, Thompson JW, Williams LSJ, Louie G, Skime MK, Wang L, Riva-Posse P, McDonald WM, Bobo WV, Craighead WE, Krishnan R, Weinshilboum RM, Dunlop BW, Millington DS, Rush AJ, Frye MA, Kaddurah-Daouk R, Mood Disorders Precision Medicine Consortium (MDPMC). Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. J Affect Disord. 2020 Mar 1;264:90–97.
Journal cover image

Published In

J Affect Disord

DOI

EISSN

1573-2517

Publication Date

March 1, 2020

Volume

264

Start / End Page

90 / 97

Location

Netherlands

Related Subject Headings

  • Retrospective Studies
  • Psychiatry
  • Phenotype
  • Humans
  • Depressive Disorder, Major
  • Carnitine
  • 52 Psychology
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 17 Psychology and Cognitive Sciences